Zhaoke Ophthalmology (HKSE:06622) Total Equity: HK$1,740.92 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06622 Zhaoke Ophthalmology Ltd HKSE:06622
47 GF Score
Price HK$2.53
GF Value HK$2.60
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Zhaoke Ophthalmology Total Equity?

Zhaoke Ophthalmology HKSE:06622 +1.61% 47 Total Equity is HK$1,740.92 Mil as of Dec. 2025. GuruFocus rates HKSE:06622 with a GF Score™ of 47/100 and a GF Value™ of HK$2.60 (Fairly Valued). The stock has 5 warning signs investors should review.

Zhaoke Ophthalmology's total equity for the quarter that ended in Dec. 2025 was HK$1,740.92 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Zhaoke Ophthalmology Total Equity Historical Data

* Premium members only.

The historical data trend for Zhaoke Ophthalmology's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhaoke Ophthalmology Total Equity Chart

Zhaoke Ophthalmology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 3,055.64 2,622.46 2,240.41 2,028.66 1,740.92

Zhaoke Ophthalmology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,240.41 2,188.70 2,028.66 1,864.82 1,740.92
HKSE:06622
47GF Score
Zhaoke Ophthalmology Ltd HKSE:06622
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhaoke Ophthalmology Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Zhaoke Ophthalmology's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=2137.988-397.066
=1,740.92

Zhaoke Ophthalmology's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=2137.988-397.066
=1,740.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of HK$1,740.92 Mil mean?
Zhaoke Ophthalmology (HKSE:06622) has a Total Equity of HK$1,740.92 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Zhaoke Ophthalmology and its competitors.
Is Zhaoke Ophthalmology's Total Equity too high?
Zhaoke Ophthalmology's current Total Equity is HK$1,740.92 Mil. Overall, Zhaoke Ophthalmology has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhaoke Ophthalmology's Total Equity compare to VRTX and REGN?
Zhaoke Ophthalmology's Total Equity of HK$1,740.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Zhaoke Ophthalmology and its competitors. Zhaoke Ophthalmology's current Total Equity is HK$1,740.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhaoke Ophthalmology stock overvalued right now?
Based on GuruFocus' analysis, Zhaoke Ophthalmology (HKSE:06622) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.60, compared to a current price of HK$2.53 — trading 2.7% below its estimated fair value. The current Total Equity is HK$1,740.92 Mil. Zhaoke Ophthalmology's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Zhaoke Ophthalmology (HKSE:06622), the current Total Equity is HK$1,740.92 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhaoke Ophthalmology (HKSE:06622) Overvalued in 2026?

Based on GuruFocus' analysis, Zhaoke Ophthalmology stock appears to be undervalued. The current stock price of HK$2.53 is trading 2.7% below its estimated GF Value™ of HK$2.60. GuruFocus considers Zhaoke Ophthalmology to be Fairly Valued.

Key valuation signals for HKSE:06622:

  • Total Equity: HK$1,740.92 Mil
  • GF Value™: HK$2.60 vs. price of HK$2.53 (2.7% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the HKSE:06622 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhaoke Ophthalmology Business Description

Other Exchanges 9FX:Germany
Address No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangdong Province, Guangzhou, CHN
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address unmet medical needs. The company has three flagship drug assets progressing towards potential market approval: NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Chinese Mainland, South Korea, and Others, of which it generates maximum revenue from Chinese Mainland.
47GF Score

Get the complete analysis for HKSE:06622

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.53
Price
HK$2.60
GF Value